Key points are not available for this paper at this time.
Poly(ADP-ribose) polymerase activation is an immediate cellular response to metabolic-, chemical-, or ionizing radiation-induced DNA damage and represents a new target for cancer therapy. In this article, we disclose a novel series of substituted 4-benzyl-2 H-phthalazin-1-ones that possess high inhibitory enzyme and cellular potency for both PARP-1 and PARP-2. Optimized compounds from the series also demonstrate good pharmacokinetic profiles, oral bioavailability, and activity in vivo in an SW620 colorectal cancer xenograft model. 4-3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl-2 H-phthalazin-1-one (KU-0059436, AZD2281) 47 is a single digit nanomolar inhibitor of both PARP-1 and PARP-2 that shows standalone activity against BRCA1-deficient breast cancer cell lines. Compound 47 is currently undergoing clinical development for the treatment of BRCA1- and BRCA2-defective cancers.
Building similarity graph...
Analyzing shared references across papers
Loading...
Keith Menear
GW Pharmaceuticals (United Kingdom)
Claire Adcock
University of Sussex
Robert Boulter
Thermo Fisher Scientific (United Kingdom)
Journal of Medicinal Chemistry
Thermo Fisher Scientific (United Kingdom)
Building similarity graph...
Analyzing shared references across papers
Loading...
Menear et al. (Fri,) studied this question.
synapsesocial.com/papers/6a09790d30285ee4a1340228 — DOI: https://doi.org/10.1021/jm8001263
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: